There were 2,032 press releases posted in the last 24 hours and 425,535 in the last 365 days.

Amedisys Buys Alabama Hospice Agency

April 6, 2010 (FinancialWire) — Amedisys, Inc. (NASDAQ: AMED), a home health and hospice firm, TODAY said that it has acquired a hospice agency located in Killen, Alabama from Bluewater Healthcare Inc.

According to Amedisys, the agency covers seven counties in northwest Alabama, six which are new to Amedisys. Bluewater had annualized revenue of $900,000 in 2009.

The Louisiana-based company added that the acquisition is not expected to add materially to Amedisys earnings in 2010.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.